|Articles|October 28, 2015
Valeant Responds to Drug Distribution Criticisms
Author(s)Randi Hernandez
October 28, 2015.
Advertisement
According to a recent report from Citron Research originally highlighted in the New York Times (Oct. 19, 2015), Valeant is using phantom drug distribution companies to manipulate distribution numbers to auditors. Philidor Rx Services came on the
BioPharm International's Randi Hernandez reports on
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
2
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Expands Indication for Merck’s Winrevair in Pulmonary Arterial Hypertension
5
